Search for 'Provider:Breast Cancer Research and Treatment,'

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.

By Manso Sánchez, Luis. Breast cancer research and treatment, 2015 . 154(2):351-7. , Formato Vancouver: Llombart Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J et al. SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015 Nov;154(2):351-7.

Place Hold on SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.

By Rodríguez Peralto, José Luis. Breast cancer research and treatment, 2015 . 154(2):275-86. , Formato Vancouver: Regan MM, Pagani O, Francis PA, Fleming GF, Walley BA, Kammler R et al; SOFT and TEXT Investigators and International Breast Cancer Study Group. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat. 2015 Nov;154(2):275-86.

Place Hold on Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.

Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.

By Ciruelos Gil, Eva María. Breast cancer research and treatment, 2015 . 149(1):151-61. , Formato Vancouver: Tolaney S, Burris H, Gartner E, Mayer IA, Saura C, Maurer M et al. Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2015 Jan;149(1):151-61.

Place Hold on Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.

Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.

By Manso Sánchez, Luis. Breast cancer research and treatment, 2015 . 151(3):597-606. , Formato Vancouver: Gil Gil MJ, Bellet M, Morales S, Ojeda B, Manso L, Mesia C et al. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. Breast Cancer Res Treat. 2015 Jun;151(3):597-606.

Place Hold on Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.

By Ghanem Cañete, Ismael. Breast cancer research and treatment, 2013 . 138(2):427-35. , Formato Vancouver: Moreno-Aspitia A, Dueck AC, Ghanem-Cañete I, Patel T, Dakhil S, Johnson D et al. RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Res Treat. 2013 Apr;138(2):427-35.

Place Hold on RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.

Intraoperative molecular analysis of total tumor load in sentinel lymph node: a new predictor of axillary status in early breast cancer patients.

By Delgado Sánchez, Julio J.. Breast Cancer Research and Treatment, 2013 . 139(1):87-93. , Formato Vancouver: Peg V, Espinosa-Bravo M, Vieites B, Vilardell F, Antúnez JR, de Salas MS et al. Intraoperative molecular analysis of total tumor load in sentinel lymph node: a new predictor of axillary status in early breast cancer patients. Breast Cancer Res Treat. 2013 May;139(1):87-93.

Place Hold on Intraoperative molecular analysis of total tumor load in sentinel lymph node: a new predictor of axillary status in early breast cancer patients.

Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).

By Ciruelos Gil, Eva María. Breast Cancer Research and Treatment, 2012 , Formato Vancouver: Zambetti M, Mansutti M, Gomez P, Lluch A, Dittrich C, Zamagni C, et al. Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). Breast Cancer Res Treat. 2012 Apr;132(3):843-51.

Place Hold on Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).

Final overall survival results and effect of prolonged (a parts per thousand yen1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

By Cortés-Funes Castro, Hernán. Breast Cancer Research and Treatment, 2011 . 130(1):133-143. , Formato Vancouver: Smith I, Pierga JY, Biganzoli L, Cortes-Funes H, Thomssen C, Saracchini S, et aI. Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Res Treat. 2011;130(1):133-43.

Place Hold on Final overall survival results and effect of prolonged (a parts per thousand yen1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial